Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SPR | P35270 | 4/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11542434 | 0.80 | ADORA2A (0.45) | ADORA2AADORA2BKMT2AL3MBTL1SPR | |
| SCHEMBL11545260 | 0.80 | ADORA2A (0.45) | ADORA2AADORA2BKMT2AL3MBTL1SPR | |
| Hydrochloric Acid SCHEMBL11881444 | 0.79 | ADORA2A (0.44) | ADORA2AADORA2BKMT2AL3MBTL1SPR | |
| SCHEMBL11541422 | 0.78 | SPR (0.46) | ADORA2AADORA2BKMT2AL3MBTL1SPR | |
| SCHEMBL11129400 | 0.77 | ADORA2A (0.41) | ADORA2AADORA2BKMT2AL3MBTL1SPR | |
| SCHEMBL4409862 | 0.76 | SPR (0.50) | ADORA2AADORA2BSPRNR3C1POLB | |
| SCHEMBL11875375 | 0.75 | KMT2A (0.55) | KMT2ASPRPOLBHTTSMN1; SMN2 | |
| SCHEMBL13562830 | 0.71 | L3MBTL1 (0.67) | ADORA2AADORA2BL3MBTL1HTTSMN1; SMN2 | |
| SCHEMBL31457141 | 0.69 | SPR (0.46) | KMT2AL3MBTL1SPRNR3C1LMNA | |
| SCHEMBL14521067 | 0.69 | ADORA2A (0.65) | ADORA2AADORA2BKMT2ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865662-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2014-10-21 | — | — | US | disclosed |
| EP-2247294-B1 | MACROLIDES FOR TREATING DISEASES MEDIATED THROUGH PDE INHIBITION | BASILEA PHARMACEUTICA AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-20120277174-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2012-11-01 | — | — | US | disclosed |
| US-8173609-B2 | Macrolides useful against inflammatory and allergic diseases | BASILEA PHARMACEUTICA AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277174-A1 | NEW MACROLIDES AND THEIR USE | PDE4A, PDE4B, PDE12 | ADORA2A 2439/4885ADORA2B 1893/4885KMT2A 2566/4885 |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | PDE4A, PDE12, PDE4B | ADORA2A 2894/4885ADORA2B 2198/4885KMT2A 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.